EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Skin and systemic inflammation in adults with atopic dermatitis before and after whole‐body topical betamethasone 17‐valerate 0.1% or tacrolimus 0.1% treatment: A randomized controlled study

Lise Gether iD, Helena P I Linares iD, Sanja Kezic, Ivone Jakasa, Julie Forman, Ole E Sørensen, Heidi Storgaard, Lone Skov iD, Mads A Røpke, Filip K Knop, Jacob P Thyssen iD

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20258 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Lise Gether und 10 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Research Group for Inflammatory Skin (CORGIS), Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, …. Hauptthemen laut MEDLINE: Tacrolimus, Dermatitis, Atopic, Betamethasone Valerate, Immunosuppressive Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Innovation Fund Denmark, LEO Pharma A/S, Aage Bang's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is mainly driven by type 2 inflammation and often treated with topical agents. Studies comparing differences in biomarkers between these treatments are lacking.

Objectives

The aim of this study was to evaluate the effects of topical betamethasone 17‐valerate 0.1% and tacrolimus 0.1% ointment on skin barrier function and inflammatory biomarkers in skin and blood in adults with AD.

Methods

In this randomized parallel‐group double‐blind double‐dummy active‐comparator study design, 36 adults with AD were treated with either whole‐body topical corticosteroid (betamethasone ointment 0.1% plus placebo once daily, n = 18) or calcineurin inhibitor (tacrolimus ointment 0.1% twice daily, n = 18). At baseline, after 2 weeks of daily treatment and after further 4 weeks of twice‐weekly maintenance treatment, we evaluated AD severity, levels of natural moisturizing factor (NMF) and cytokines in the skin and blood and characterized circulating T cells.

Results

Mean AD severity at baseline corresponded to moderate disease and decreased significantly in both groups. Levels of NMF increased significantly in the tacrolimus group after 2 weeks of treatment ( p = 0.002) and tended to increase more than betamethasone at week 6 ( p = 0.06). Most skin cytokines decreased with both treatments. However, IL‐8, IL‐18, IL‐22, IP‐10, MDC, MMP‐9 and TARC were significantly more decreased with betamethasone than tacrolimus after 2 weeks, while after 6 weeks this was only the case for IL‐8 and MMP‐9. Approximate half of the systemic cytokines decreased significantly with both treatments, but betamethasone decreased MDC significantly more after 2 weeks of treatment. T‐cell characterization analyses indicated slight differences in the expression and activation of T cells between groups.

Conclusions

Topical treatment of AD with betamethasone and tacrolimus ointment effectively reduced disease severity, cutaneous and systemic inflammatory markers. Betamethasone was more effective in decreasing inflammation, but tacrolimus improved skin hydration (NMF levels) more than betamethasone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusDermatitis, AtopicBetamethasone ValerateImmunosuppressive AgentsSkinAnti-Inflammatory AgentsHumansAdultMaleFemaleDouble-Blind MethodMiddle AgedInflammationYoung AdultCytokinesAdministration, TopicalBiomarkers

Substanzen

TacrolimusBetamethasone ValerateImmunosuppressive AgentsCytokinesAnti-Inflammatory AgentsBiomarkers

Autor:innen und Institutionen

  • Copenhagen Research Group for Inflammatory Skin (CORGIS), Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • LEO Pharma A/S, Ballerup, Denmark.
  • Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
  • Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.

ORCID-Profile: Lise Gether, Helena P I Linares, Lone Skov, Jacob P Thyssen

Förderung

  • Innovation Fund Denmark
  • LEO Pharma A/S
  • Aage Bang's Foundation
  • Innovationsfonden
  • LEO Pharma
  • Kongelig Hofbuntmager Aage Bangs Fond

Zitieren

APA

Gether, L., Linares, H. P. I., Kezic, S., Jakasa, I., Forman, J., Sørensen, O. E., Storgaard, H., Skov, L., Røpke, M. A., Knop, F. K., & Thyssen, J. P. (2025). Skin and systemic inflammation in adults with atopic dermatitis before and after whole‐body topical betamethasone 17‐valerate 0.1% or tacrolimus 0.1% treatment: A randomized controlled study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20258

Vancouver

Gether L, Linares HPI, Kezic S, Jakasa I, Forman J, Sørensen OE, et al. Skin and systemic inflammation in adults with atopic dermatitis before and after whole‐body topical betamethasone 17‐valerate 0.1% or tacrolimus 0.1% treatment: A randomized controlled study. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20258

BibTeX
@article{Gether2025,
  author = {Gether, Lise and Linares, Helena P I and Kezic, Sanja and Jakasa, Ivone and Forman, Julie and Sørensen, Ole E and Storgaard, Heidi and Skov, Lone and Røpke, Mads A and Knop, Filip K and Thyssen, Jacob P},
  title = {Skin and systemic inflammation in adults with atopic dermatitis before and after whole‐body topical betamethasone 17‐valerate 0.1% or tacrolimus 0.1% treatment: A randomized controlled study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20258}
}
Kostenlos starten →